Abstract-One mechanism by which high density lipoproteins (HDLs) exert their protective effect against coronary artery disease could be related to the induction of prostacyclin (PGI 2 ) release in the vessel wall. We have recently shown that HDL increases PGI 2 production in rabbit smooth muscle cells (RSMCs) and that this increase is dependent on cyclooxygenase-2 (Cox-2). Here we analyze the mechanism by which rabbit HDL induces PGI 2 release in RSMCs. Our results show that although HDL 2 and HDL 3 share a similar capacity to induce Cox-2 protein levels, HDL 3 stimulates a higher PGI 2 release than does HDL 2 , probably because of their relative arachidonate contents. Acetylsalicylic acid pretreatment (300 mol/L, 30 minutes) significantly reduced the HDL-induced PGI 2 release, suggesting that both preexisting and induced Cox-2 activities were involved in the HDL effect. Ca 2ϩ -dependent cytosolic phospholipase A 2 (cPLA 2 ) and Cox-1 protein levels were not altered by HDL. Dexamethasone (2 mol/L), which also inhibited the HDL-induced PGI 2 release, reduced significantly both Cox-2 mRNA and protein levels without affecting cPLA 2 and Cox-1 protein levels. In addition, methylarachidonyl fluorophosphonate, a potent inhibitor of cPLA 2 , did not produce any effect on HDL-induced PGI 2 release. In the presence of cycloheximide, Cox-2 mRNA levels were induced by HDL and inhibited by dexamethasone, suggesting that HDL and dexamethasone work in the absence of de novo protein synthesis. These results indicate an early effect of HDL on PGI 2 biosynthesis, specifically increasing Cox-2. PD98059, an inhibitor of mitogen-activated protein kinase kinase, completely inhibited HDL-induced PGI 2 release, whereas GF109203X, a protein kinase C inhibitor, had no effect. Thus, HDL induces PGI 2 synthesis by a mechanism dependent on the mitogen-activated protein kinase pathway but independent of protein kinase C. 
S
everal epidemiological and experimental studies have shown that HDLs have a protective effect against coronary artery disease. [1] [2] [3] [4] [5] The most widely accepted mechanism for this protective effect is through an enhanced reverse cholesterol transport. 6, 7 However, other mechanisms such as induction of prostacyclin (PGI 2 ) synthesis in the vessel wall have been postulated. The stimulatory effect of HDL on PGI 2 production by both endothelial and smooth muscle cells (SMCs) has been widely demonstrated. 8 -12 In contrast, the effect of low density lipoprotein (LDL) on the biosynthesis of prostanoids is unclear: they can stimulate, inhibit, or have no effect on prostanoid synthesis. [11] [12] [13] [14] [15] This variable effect of LDL has been related to its degree of oxidation. 16, 17 PGI 2 is a vasodilator prostaglandin that is synthesized by blood vessels and contributes to the maintenance of vascular tone. 18, 19 Other actions of PGI 2 include inhibition of platelet aggregation and adhesion, inhibition of SMC growth, inhibition of leukocyte activation and adhesion, and reduction of cholesteryl ester accumulation in vessel wall cells. These biological actions of PGI 2 suggest that it is an endogenous antiatherogenic molecule. 20 The rate-limiting step in the conversion of arachidonic acid to prostaglandins and other eicosanoids is at the level of cyclooxygenase (Cox; prostaglandin G/H synthase; E.C. 1.14.99.1). Two isoforms of Cox have been described: Cox-1 and Cox-2. Cox-1 is present in several cells and tissues in relatively stable levels, 21 although small increases in enzyme content can occur after stimulation with hormones or growth factors. 22, 23 Cox-2 is usually absent in resting cells, and its expression is increased by serum, cytokines, mitogens, and different growth factors. 21,24 -26 We have recently shown that HDL increases eicosanoid production in SMCs by a Cox-2-dependent mechanism. 27 In the present study, we analyzed the involvement in this process of both preexisting and induced Cox-2 activities, as well as the role of other enzymes implicated in the formation of prostaglandins and leukotrienes, such as cytosolic phospholipase A 2 (cPLA 2 ). 28 In addition, we investigated the intracellular signaling mechanisms by which HDL exerts this effect. Our results indicate that HDL induces PGI 2 biosynthesis by both preexisting and induced enzyme, specifically increasing Cox-2 mRNA and protein levels, and that HDL induces PGI 2 synthesis by a mechanism dependent on the mitogen-activated protein kinase (MAPK) pathway but independent of protein kinase C (PKC).
Methods

Materials
Cell culture medium and reagents were purchased from Gibco Laboratories. [␣-
32 P]dCTP (3000 Ci/mmol), nylon membranes (Hybond-N), and the ECL chemiluminescent detection system were from Amersham. The 6-keto-PGF 1␣ enzyme immunoassay (EIA) kit and methylarachidonyl fluorophosphonate (MAFP) were from Cayman Chemical Co. Actinomycin D, cycloheximide, dexamethasone, and aspirin (acetylsalicylic acid; ASA) were from Sigma Chemical Co. Precast polyacrylamide gels and nitrocellulose membranes were from Bio-Rad Laboratories. Ultraspec was purchased from Biotecx Laboratories Inc. PD98059 and GF109203X were from Alexis Corp. Other materials and chemicals were obtained from other commercial sources.
Lipoprotein Isolation
Lipoproteins were obtained by sequential ultracentrifugation of normolipemic rabbit plasma in a Beckman 50.2 Ti rotor at densities between 1.019 and 1.063 g/mL (LDL), 1.063 and 1.125 g/mL (HDL 2 ), 1.125 and 1.210 g/mL (HDL 3 ), and 1.063 and 1.210 g/mL (HDL). Lipoproteins were recentrifuged, dialyzed, and assayed for protein and lipid contents. 27 Lipoproteins used in the experiments were Ͻ2 weeks old and did not contain detectable thiobarbituric acid-reactive substances.
Isolation of Rabbit Aortic SMCs
RSMCs were obtained by gentle scraping of the medial layer of male New Zealand White rabbit aortas after endothelial layer removal. Cells were incubated at 37°C in a humidified atmosphere of 5% CO 2 in Ham's F12-Dulbecco's modified Eagle's medium (8:2, vol/vol) supplemented with 20% fetal calf serum (FCS). Antibiotics (100 U/mL penicillin and 0.1 mg/mL streptomycin) were added to the culture medium. RSMCs were identified by their growth behavior, morphology, and immunofluorescence. 29 
Cell Culture and Supernatant Determinations
Cells between the third and seventh passages were grown as described above. At subconfluence fresh medium was added to the wells, and 24 hours later cells were washed 3 times with FCS-free medium and incubated with lipoproteins. When experiments were addressed to inhibit baseline Cox activity, cells were pretreated for 30 minutes with 300 mol/L ASA, an inhibitor of the 2 Cox isoforms. 30 They were then incubated with ASA (300 mol/L) or dexamethasone (2 mol/L) for 2 hours; with actinomycin D (1 g/mL) or cycloheximide (2 g/mL) for 45 minutes; or with MAFP (1 mmol/L), PD98059 (30 and 50 mol/L), or GF109203X (0.5 and 20 mol/L) for 30 minutes before HDL treatment. After lipoprotein incubations (1, 2, 3, 6, 8, or 24 hours), the culture medium was kept frozen at Ϫ80°C. PGI 2 in the supernatants was measured as 6-keto-PGF 1 ␣ , its stable hydrolysis product, by an EIA kit.
Western Blot Analysis
RSMCs were cultured as described above. Cells were stimulated with lipoproteins for 6 hours. Cell monolayers were washed with PBS and lysed with 50 mmol/L Tris, 1 mmol/L EDTA, and 0.1% Triton. Total protein was separated by SDS-polyacrylamide gel electrophoresis on 4% to 15% gradient polyacrylamide gels with a mini-PROTEAN II dual slab cell (Bio Rad). Proteins from polyacrylamide gels were blotted onto nitrocellulose membranes at 40 mA for 1 hour at 4°C. The residual binding capacity of the membranes was blocked with 5% nonfat milk in 10 mmol/L Tris (pH 7.5), 100 mmol/L NaCl, and 0.1% Tween 20. 31 Blots were incubated with monoclonal antibodies against human Cox-2 (C22420, Transduction Laboratories) and cPLA 2 (sc-454, Santa Cruz Biotechnology, Inc) or with a goat polyclonal antibody against a peptide corresponding to amino acids mapping at the carboxy terminus of the human Cox-1 (sc-1752, Santa Cruz Biotechnology, Inc). Bound antibody was detected by using the appropriate horseradish peroxidase-conjugated antibody. Signals were detected with the ECL on a standard x-ray system.
RNA Blot Analysis
RSMCs were cultured as previously described. After lipoprotein incubations, stimulations were halted by the addition of ice-cold isolation reagent Ultraspec RNA (1 mL/21-cm 2 dish). RNA samples were fractionated in 1.1% agarose gels containing formaldehyde. RNA was transferred by capillarity to Hybond membranes and UV-cross-linked. Filters were prehybridized and hybridized at 42°C in 50% formamide, 1 mol/L NaCl, 50 mmol/L NaH 2 PO 4 (pH 6.3), 7.5ϫ Denhardt's solution, 1% SDS, 10% dextran sulfate, and 200 g/mL denatured salmon sperm DNA. 32 The human Cox-2 cDNA, kindly provided by Dr Hla, 24 and the rabbit Cox-1 cDNA 27 were used as probes. Washes were carried out under moderate-stringency conditions. Filters were exposed to Agfa Curix RP2 x-ray film at Ϫ70°C. Filters were rehybridized with a ribosomal cDNA probe to assess the amount of RNA. 33 
Assay of cPLA 2 Enzymatic Activity
RSMCs were cultured as indicated above and incubated with HDL (150 g cholesterol per mL) for 1 hour. cPLA 2 activity was assayed by using the cPLA 2 kit from Cayman Chemical Co according to the manufacturer's instructions. In brief, the cytosolic fraction from RSMC cultures was incubated with the substrate arachidonylthiophosphatidylcholine (ATPC). Enzymatic hydrolysis of ATPC re- Figure 1 . A, Effect of HDL subfractions on PGI 2 release. RSMCs were cultured in the presence of 150 g cholesterol per mL of HDL cholesterol for 24 hours, and 6-keto-PGF 1␣ levels were measured by EIA. Results are expressed as ng/mL 6-keto-PGF 1␣ and are shown as meanϮSEM of 3 independent experiments run in triplicate. (Deviations Ͻ5% of the mean do not appear in the computer-originated graphs.) PϽ0.05: *versus control cells (saline); ϩversus HDL 2 -treated cells. B, Effect of HDL subfractions on Cox-2 protein levels. RSMCs were cultured in the presence or absence of 150 g HDL cholesterol per mL for 6 hours. LDL (150 g cholesterol per mL) was used as a control. Cox-2 protein levels were analyzed by Western blot as described in Methods. The migration of molecular-weight markers used to estimate size is indicated on the left. leases free thiol, which is then converted into 5-thiol-2-nitrobenzoic acid by Ellman's reagent [5,5Ј-dithiobis(2-nitrobenzoic acid]. 5-Thiol-2-nitrobenzoic acid formation is determined by spectrophotometric analysis at 414 nm.
Statistical Analysis
Data are presented as meanϮSEM. Means were compared by using ANOVA. Differences were considered significant at PϽ0.05.
Results
Effect of HDL 2 and HDL 3 Subfraction on PGI 2 Release and Cox-2 Protein Levels
RSMCs were incubated with HDL 2 , HDL 3 , or the complete HDL fraction (150 g cholesterol per mL) for 24 hours, and PGI 2 release was measured. Results showed that HDL 3 induced a significantly higher release than did HDL 2 (4.18Ϯ0.49 and 2.14Ϯ0.26 ng/mL, respectively; PϽ0.0001; Figure 1A ). In contrast, all of the fractions induced similar Cox-2 protein levels with respect to control cells ( Figure 1B) . Thus, subsequent studies were performed with the total HDL fraction.
Effect of ASA Pretreatment, Cycloheximide, and Actinomycin D on PGI 2 Release Induced by HDL HDL (150 g cholesterol per mL) induced a time-dependent increase in PGI 2 production in RSMCs. ASA pretreatment (300 mol/L, 30 minutes) significantly reduced HDLinduced PGI 2 release (Figure 2A ). The ASA-produced inhibition was lost in a time-dependent fashion; it was highest at 2 hours (74.8Ϯ1.2%) and decreased after 8 (43.2Ϯ9.3%) and 24 (21.4Ϯ9.1%) hours of incubation. The effect of ASA pretreatment on control cells was maintained over time.
Both cycloheximide (2 g/mL), a protein synthesis inhibitor, and actinomycin D (1 g/mL) , an inhibitor of transcription, abolished PGI 2 release induced by HDL (the Table) .
Taken together, these results suggest that both basal and de novo synthesized Cox activities are involved in PGI 2 production induced by HDL.
Effect of Dexamethasone on PGI 2 Release Induced by HDL
In ASA-pretreated cells, dexamethasone (2 mol/L), a Cox-2 inhibitor by transcriptional and posttranslational mechanisms, 34, 35 significantly reduced the HDL-induced PGI 2 release. However, PGI 2 values in the presence of dexamethasone did not reach baseline levels (31.1Ϯ7.5% at 2 hours, 40.9Ϯ8.6% at 8 hours, and 49.4Ϯ12.4% at 24 hours of incubation; Figure 2B ). Furthermore, in ASA-pretreated SMCs maintained under ASA treatment for a prolonged incubation time (2, 8, or 24 hours), PGI 2 synthesis induced by HDL was partially inhibited (HDL 3.14Ϯ0.69 ng/mL versus HDL plus ASA 1.22Ϯ0.38 ng/mL at 24 hours of incubation; Figure 2B ). In contrast, ASA completely inhibited PGI 2 release promoted by FCS (FCS 68.6Ϯ13.0 ng/mL versus FCS plus ASA 0.45Ϯ0.08 ng/mL). 27 Thus, ASA abolishes the Figure 4 ). In addition, cPLA2 activity levels from RSMCs activated by HDL were similar to those from controls (10.1Ϯ3.1 and 8.9Ϯ2.4 pmol ⅐ min Ϫ1 ⅐ mg Ϫ1 protein, respectively).
Effect of Cycloheximide and Actinomycin D on PGI 2 Release
Effect of Cycloheximide and Dexamethasone on Cox-2 mRNA Levels Induced by HDL
Cycloheximide (2 g/mL, 3 hours), which inhibited PGI 2 release induced by HDL (the Table) , produced a superinduction of Cox-2 mRNA, which was more significant in HDL than in control cells (saline or LDL-treated cells) ( Figure 5A ). In the presence of cycloheximide, dexamethasone efficiently inhibited superinduced Cox-2 mRNA levels in both control and HDL-treated cells ( Figure 5B ). These results indicate that de novo protein synthesis is not a requirement for the modulation of Cox-2 mRNA levels by HDL and dexamethasone. In contrast, cycloheximide prevented the inhibition by dexamethasone of Cox-2 mRNA levels induced by FCS.
Effect of an MAPK Kinase and PKC Inhibitors on PGI 2 Release Induced by HDL
PD98059 (30 mol/L), a specific inhibitor of the activation of MAPK kinase, 38,39 completely inhibited PGI 2 release induced by HDL in SMCs ( Figure 6 ). In contrast, GF109203X (20 mol/L), a protein kinase C (PKC) inhibitor, 40 had no effect on PGI 2 release induced by HDL. However, the effect of PD98059 and GF109203X on HDL-induced Cox-2 mRNA levels was negligible (data not shown).
Discussion
Previous reports have indicated that the levels of PGI 2 release by cells treated with HDL depend, at least in part, on HDL cholesteryl arachidonate content. 11, 12 We have recently shown that HDL increases eicosanoid production in RSMCs by a Cox-2-dependent mechanism. 27 We now report that in RSMCs, rabbit HDL promotes PGI 2 release through both preexisting and induced Cox activity. HDL 3 is more effective than HDL 2 in inducing PGI 2 release, although both HDL fractions induce similar levels of Cox-2 protein. HDL 3 has a higher cholesteryl arachidonate content than does HDL 2 and thus, the former may provide a larger supply of substrate for Cox enzymatic activity. 10, 13 On the other hand, ASA pretreatment significantly reduced PGI 2 release induced by HDL. Thus, HDL may promote SMC PGI 2 synthesis acting as a substrate donor and as an inducer of Cox-2. The prominent role of Cox-2 over Cox-1 in HDL-induced PGI 2 release has been suggested by the effectiveness of NS-398, a selective Cox-2 inhibitor; in addition, inhibition of both Cox isoforms with ASA only slightly augmented the effect produced by NS-398 or dexamethasone. 27 However, a coordinate induction of Cox-2 and cPLA 2 has been reported in many cell types, 41, 42 and it appears that glucocorticoids cannot inhibit Cox-2 only but also Cox-1 and cPLA 2 activities. [43] [44] [45] [46] cPLA 2 is an arachidonyl-selective PLA 2 , 28 involved in PGI 2 synthesis induced by cytokines and growth factors in several cell types. [47] [48] [49] A possible involvement of Cox-1 and cPLA 2 could therefore not be ruled out. In this article, we show that Cox-2 protein levels but not those of Cox-1 or cPLA 2 were induced by HDL. HDL did not increase cPLA 2 activity in RSMCs, and high concentrations of MAFP, a potent inhibitor of cPLA 2 , [35] [36] [37] did not inhibit PGI 2 release induced by HDL. Moreover, dexamethasone reduced the PGI 2 release induced by HDL basically through the inhibition of Cox-2 mRNA and protein levels without affecting cPLA 2 and Cox-1 protein levels. Thus, cPLA 2 does not seem to be a rate-limiting enzyme in the HDL effect on PGI 2 release. In fact, the slow and progressive time course of HDL-induced PGI 2 synthesis 11, 12, 27 differs markedly from the rapid effects of the phospholipase activators. [47] [48] [49] To further characterize the mechanism by which HDL upregulates Cox-2 mRNA levels, we analyzed whether de novo protein synthesis was a requirement. Cycloheximide, a protein synthesis inhibitor, did not block HDL induction of Cox-2 mRNA levels, suggesting a mechanism independent of de novo protein synthesis. In contrast, cycloheximide potentiated the HDL upregulation of Cox-2 mRNA levels. The superinduction of Cox-2 mRNA levels and other early genes by cycloheximide has been previously shown. 35 Several mechanisms have been proposed to explain the superinduction by cycloheximide of inducible mRNAs, including inhibition of the mRNA degradation machinery. 50 Dexamethasone can block Cox-2 by transcriptional and posttranslational mechanisms. 34, 35 Our results show that dexamethasone did not inhibit Cox-2 mRNA levels induced by FCS in the presence of a protein synthesis inhibitor (cycloheximide). It has been shown that RNA and protein synthesis inhibitors reverse the effect of dexamethasone, suggesting that dexamethasone inhibition is mediated by 1 or more newly synthesized proteins. 34 However, in the presence of cycloheximide, dexamethasone efficiently inhibited Cox-2 mRNA levels induced by HDL. Thus, dexamethasone could inhibit HDL-induced Cox-2 mRNA levels by acting mainly at the transcriptional level. Indeed, a potential glucocorticoid response element has been described in the Cox-2 gene. 51 HDL activates a number of signaling pathways 52-54 whose role in its cellular effects (intracellular cholesterol efflux, PGI 2 release, cell proliferation, etc) is not completely understood. We show that the MAPK pathway is involved in the HDL-induced PGI 2 release. Our present results with GF109203X and previous data with calphostin C, 27 2 specific inhibitors of PKC, suggest that HDL-induced PGI 2 release is signaled through MAPK activation, independent of PKC. Although PKC and MAPK activations are interrelated, some Cox-2 inducers work by a PKC-independent mechanism. 54 -56 Recently, several authors have shown data linking the MAPK pathway, but not that of PKC, to PGI 2 production induced by different molecules. [57] [58] [59] In contrast, PKC seems to play a key role in HDL-induced cholesterol efflux. 52 However, neither GF109203X nor PD98059, a specific inhibitor of MAPK kinase, was able to block the early upregulation of Cox-2 mRNA levels by HDL; thus, alternative signaling could be involved in the process. Taking into consideration that the MAPK pathway is usually linked to different cellular processes triggered by receptors 60, 61 and that purified apo A-I reproduces the binding parameters of HDL 62, 63 and partially mimics the HDL effect on PGI 2 synthesis, 27 this HDL effect could be receptor mediated.
Eicosanoids are a widespread lipid-mediator system for intracellular signaling and hence, have multiple cellular actions such as regulation/modulation of vessel tone, platelet and neutrophil function, and fibrinolysis. Thus, it is not surprising that numerous events in the pathogenesis of atherosclerosis are associated with an altered formation of eicosanoids. 64, 65 HDL could exert its protective effect against coronary artery disease, at least in part, through the upregulation of PGI 2 biosynthesis. HDL would act through a multiple mechanism: providing substrate to the preexisting 
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and/or de novo Cox enzyme, inducing de novo synthesis of Cox-2 protein, and stabilizing the induced PGI 2 . 12,27,66 Plasma HDLs can contact directly with vascular SMCs when an atherosclerotic plaque or a healthy vessel suffers endothelial denudation. 67 Cox-2 induction may thus contribute to the cardiovascular protection exerted by HDL as part of a defense mechanism triggered to limit the deleterious effect of minimal damage to the vessel wall. Supporting this hypothesis, previous reports have demonstrated that augmenting PGI 2 synthesis in angioplasty-injured carotid arteries resulted in inhibition of thrombosis. 68 Although further studies are needed to understand the contribution of the different HDL effects to its protective cardiovascular properties, the present analysis provides new light on the mechanism by which HDL increases PGI 2 production in vessel wall cells.
